AI and Biopharma Leaders Converge at Morgan Stanley's Shanghai Symposium

The Morgan Stanley China Biopharma Symposium will take place in Shanghai on 18 June 2026. The event will explore the international expansion of Chinese biotech therapies and the role of AI in drug discovery. Dr. Alex Zhavoronkov, a leading figure in the field, will deliver a keynote address on AI-driven innovation. Dr. Zhavoronkov’s keynote will centre on AI-Driven Drug Discovery in China: Accelerating from Hit to Clinic. His presentation will also highlight the current progress and future potential of AI in biopharma. The symposium itself aims to foster collaboration and cross-border partnerships to advance Chinese biopharma on a global scale.

Insilico Medicine, led by Dr. Zhavoronkov, has developed advanced AI platforms for drug discovery. Their Pharma.AI system supports closed-loop workflows, using iterative learning from biological assays to refine its models. The company’s MMAI Gym serves as a dual-purpose tool for both developing and benchmarking AI models.

Since 2021, Insilico has nominated 31 preclinical candidate molecules. Of these, 13 have received Investigational New Drug (IND) approvals. The platform also extends beyond medicine, with applications in advanced materials science and agriculture. The firm’s focus includes addressing major clinical needs such as fibrosis, oncology, and obesity. The symposium will bring together industry leaders to discuss AI’s growing role in drug development. Insilico Medicine’s contributions, including its AI platforms and preclinical advancements, will be a key topic. The event seeks to drive innovation and strengthen international cooperation in biopharma.